Key Takeaway: Prelude Therapeutics has announced its financial results for the second quarter of 2026, highlighting the upcoming initiation of a Phase 1 study for PRT13722, an oral KAT6A degrader aimed at treating HR+ breast cancer. The company also presented promising preclinical data at the AACR Annual meeting, showcasing the drug's differentiated profile.
Market Sentiment Analysis
POSITIVE FACTORS
Initiation of Phase 1 study for PRT13722 expected soon.
PRT13722 shows a differentiated profile in preclinical data.
Targeting HR+ breast cancer with a first-in-class treatment.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+194%
120-day peak, hindsight
Typical move
8.2%
average across 4 past catalysts
Cash runway
~30 mo
Minimal dilution risk
Lead asset
PRT3789
Phase 1 · Advanced Solid Tumor
Full Press Release Details
The Company expects to initiate its Phase 1 study of PRT13722, a first-in-class highly-selective oral KAT6A degrader in HR+ breast cancer in the fourth quarter Presented preclinical data demonstrating differentiated profile of PRT13722, at the American Association for Cancer Research (AACR) Annual
Frequently Asked Questions
What is PRT13722?
PRT13722 is a first-in-class highly-selective oral KAT6A degrader.
When will the Phase 1 study of PRT13722 begin?
The Phase 1 study of PRT13722 is expected to start in the fourth quarter of 2026.
What type of cancer does PRT13722 target?
PRT13722 targets HR+ breast cancer.
Where was the preclinical data for PRT13722 presented?
The preclinical data was presented at the American Association for Cancer Research (AACR) Annual meeting.